A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer

Chih Ming Su, Ting Yu Chang, Hui Ping Hsu, Hui Huang Lai, Jie Ning Li, Yu Jhen Lyu, Kuang Tai Kuo, Ming Te Huang, Jen Liang Su, Pai Sheng Chen

研究成果: 雜誌貢獻文章

4 引文 斯高帕斯(Scopus)

摘要

Epidermal growth factor receptor (EGFR) is commonly overexpressed in breast cancer and is associated with poor clinical outcomes; however, an increasing number of patients have shown a poor effective response to EGFR tyrosine kinase inhibitors (EGFR-TKI). Here, we found that AXL expression was positively correlated with poor progression in breast cancer patients. Suppression of AXL by an anti-tumor protein, E1A, enhanced EGFR-TKI (gefitinib, erlotinib and lapatinib) sensitization, resulting in significant inhibition of tumor growth in breast cancer cells. Additionally, AXL overexpression dramatically impaired E1A-mediated EGFR-TKI sensitization. These findings show that downregulation of AXL expression by E1A contributes to sensitization to EGFE-TKI in breast cancer, suggesting that combinatorial therapy of AXL inhibitors or E1A gene therapy with EGFR-TKI may be a potential therapeutic strategy for treatment of breast cancer patients.
原文英語
頁(從 - 到)63924-63936
頁數13
期刊Oncotarget
7
發行號39
DOIs
出版狀態已發佈 - 2016

ASJC Scopus subject areas

  • Oncology

指紋 深入研究「A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer」主題。共同形成了獨特的指紋。

  • 引用此

    Su, C. M., Chang, T. Y., Hsu, H. P., Lai, H. H., Li, J. N., Lyu, Y. J., Kuo, K. T., Huang, M. T., Su, J. L., & Chen, P. S. (2016). A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer. Oncotarget, 7(39), 63924-63936. https://doi.org/10.18632/oncotarget.11737